Facing a critical rise in gram-negative bacterial resistance, the health community confronts a formidable challenge, as these infections now rank as the third leading cause of death in the US, claiming around 48,000 lives annually due to antimicrobial resistance.
Melinta Therapeutics, a pioneer in advanced antibiotic treatments, targets these resistant infections, focusing on those present in hospital settings. Most recently, Melinta worked alongside Cidara Therapeutics to garner FDA approval in 2023 for REZZAYO™ in the US. REZZAYO™ is breakthrough treatment for refractory and complicated urinary tract infections. UTIs in immunocompromised patients, males, pregnant patients, and those associated with sepsis, fever, kidney stones, urinary catheters, or involving the kidneys are considered complicated.
Melinta Therapeutics, Originating as Rib-X Pharmaceuticals in 2000, has navigated through acquisitions, leadership changes, and a rebranding journey, culminating in a bankruptcy filing in 2019. Under the leadership of Christine Ann Miller, who took the helm in 2020, the company has made a remarkable turnaround. Implementing a growth strategy centered on a people-first approach, Miller revitalized the company culture and mission, steering Melinta towards significant clinical advancements and ensuring access to affordable treatments.
Christine Ann Miller, an RPI alumna with a BS in Chemical Engineering, transitioned from engineering at Merck to management roles across the pharmaceutical sector before joining Melinta. Her leadership has not only elevated employee engagement from 69% to 94% but also achieved the company’s first product approval while under new management–their antibiotic KIMYRSA™–in 2021, marking a new era for Melinta Therapeutics.
The Products
Melinta Therapeutics boasts a diverse pipeline, predominantly targeting the growing crisis of antibiotic resistance. Prior to 2019, it had already secured approval for several drugs, including BAXDELA® for skin infections, acquired in 2006 and approved in 2017.
In 2017, Melinta expanded its portfolio with the purchase of MINOCIN®, ORBACTIV™, and VABOMERE®, elevating its offerings beyond the lone BAXDELA®.
ORBACTIV™, approved in 2014, treats bacterial skin infections in a single dose. Its successor, KIMYRSA™, offers a new hour-long infusion format, approved in 2021 under Christine’s leadership, catering to those unresponsive to single-dose treatments.
In 2022, Melinta acquired the rights to sell TOPROL-XL® in the US, expanding their portfolio to include hypertensive medications rather than just antimicrobial solutions.
REZZAYO™ gained EU approval in January 2024 following the release of positive results in phase 2 and 3 clinical trials for the treatment of Invasive Candidiasis.
Invasive candidiasis is an infection caused by Candida. Unlike Candida infections in the mouth and throat (“thrush”) or vaginal yeast infections, invasive candidiasis is a serious infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body. Candidemia, a bloodstream infection with Candida, is a common infection in hospitalized patients.
REZZAYO™ is the first new medication for the treatment of Invasive Candidiasis in the past 15 years, offering hope for patients who do not respond to other treatment options.
The Future
Melinta Therapeutics, in partnership with Venatorx Pharmaceuticals, is currently developing Cefepime-taniborbactam, an innovative antibiotic aimed at treating UTIs and acute Poly Nephritis. This collaboration has yielded promising outcomes, notably a successful Phase 3 trial reported in February 2024. Despite this progress, their FDA application encountered a hiccup, rejected due to gaps in data on the drug’s chemical makeup and testing procedures. Fortunately, this setback isn’t related to safety or efficacy concerns, sidestepping the need for further clinical trials. The FDA’s request for additional data represents a delay, but Melinta and Venatorx are steadfast in their pursuit of bringing this antibiotic to market.
Beyond drug development, Melinta recognizes the necessity of broader systemic changes to truly revolutionize antibiotic prescription practices in hospitals. Unfortunately, hospitals need to turn a profit, just like any other business. The current reimbursement model, which compensates hospitals at a fixed rate for antibiotics, disincentivizes the adoption of innovative, albeit pricier, treatments. This economic dynamic hinders the introduction of advanced therapies into hospital settings.
Christine Ann Miller has taken this challenge personally, spearheading efforts for substantial policy reform. As the chair of the Antimicrobial Working Group—a consortium of pharmaceutical companies united by a common goal—she is actively advocating for changes in reimbursement policies, investment frameworks, and drug approval processes. The group aims to dismantle the barriers to accessing cutting-edge treatments through legislative initiatives like the DISARM Act and strategic engagement with regulatory bodies such as Medicare and Medicaid.
The Antimicrobial Working Group envisions a future in which every patient has unfettered access to the most efficacious treatments available for their diagnosis, regardless of cost.